Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment.
OBJECTIVE
The mineralocorticoid receptor (MR; also known as NR3C2) plays important roles in the modulation of blood pressure. The effect of NR3C2 polymorphisms on antihypertensive response to enalapril was investigated.


METHODS
Two hundred and seventy nine essential hypertension patients treated with enalapril were genotyped for two NR3C2 tagSNPs, rs5522 and rs2070950, by Sequenom MassArray™ technology.


RESULTS
The reductions in diastolic blood pressure (DBP) were significantly greater in AA homozygotes compared with AG+GG genotype carriers for the rs5522 polymorphism (p = 0.009), and the reductions in DBP were greater in GG homozygotes compared with GC+CC genotype carriers for the rs2070950 polymorphism, with marginal significance (p = 0.065). Stepwise multiple regression analysis indicated that significant predictors of DBP reduction were baseline DBP (p < 0.001), waist:hip ratio (p = 0.001) and rs5522 genotype (p = 0.003).


CONCLUSIONS
NR3C2 rs5522 affects blood pressure response to enalapril treatment and may serve as a useful pharmacogenomic marker of antihypertensive response to enalapril in essential hypertension patients.
Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan 410078, PR China.
Jian-Quan
JQ
Luo
Lu-Yan
LY
Wang
Fa-Zhong
FZ
He
Ning-Ling
NL
Sun
Gen-Fu
GF
Tang
Jia-Gen
JG
Wen
Zhi-Ying
ZY
Luo
Zhao-Qian
ZQ
Liu
Hong-Hao
HH
Zhou
Xiao-Ping
XP
Chen
Wei
W
Zhang
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D044466:Asian People; D001794:Blood Pressure / Q000187:drug effects; D004656:Enalapril / Q000008:administration & dosage; D000075222:Essential Hypertension; D005260:Female; D056726:Genetic Association Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D018161:Receptors, Mineralocorticoid / Q000235:genetics*; D012084:Renin-Angiotensin System / Q000187:drug effects*
D000806:Angiotensin-Converting Enzyme Inhibitors; C561839:NR3C2 protein, human; D018161:Receptors, Mineralocorticoid; D004656:Enalapril